Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma
Source abstract
Abstract
ABSTRACT Acquired resistance to both targeted therapies and immunotherapies in cancer presents major clinical challenges, yet the molecular mechanisms underlying cross‐resistance remain poorly understood. We hypothesized that loss of specific microRNAs (miRNAs) could potentiate melanoma resistance to both targeted drugs and CD8 + T cell‐mediated cytotoxicity. Through genome‐wide miRNA CRISPR knockout screening integrated with cellular models, longitudinal clinical samples, and in vivo experiments, we identified miR‐18a as a pivotal upstream regulator of pleiotropic resistance in melanoma. We show that miR‐18a deficiency drives resistance through two distinct mechanisms: derepressing AJUBA‐regulated Hippo signaling during MAPK inhibition, and enhancing THBS1–CD47 interactions that impair the immunological synapse between tumor cells and CD8 + T cells. Furthermore, hnRNP A1 plays an essential role in modulating miR‐18a expression, thereby mediating cross‐resistance. These findings suggest that targeting non‐coding RNA vulnerabilities may represent a promising therapeutic strategy to overcome complex resistance mechanisms and improve clinical outcomes in melanoma.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hippo pathway signaling and YAP/TAZ · Cancer Immunotherapy and Biomarkers · Melanoma and MAPK Pathways
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacology State Key Laboratory of Experimental Hematology The Province and Ministry Co‐sponsored Collaborative Innovation Center for Medical Epigenetics Tianjin Key Laboratory of Inflammation Biology School of Basic Medical Sciences Tianjin Medical University Cancer Institute and Hospital Tianjin Medical University Tianjin China
Oujiang Laboratory Wenzhou Medical University Wenzhou China
Department of Bone and Soft Tissue Tumor Tianjin Medical University Cancer Institute and Hospital Key Laboratory of Cancer Prevention and Therapy State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine National Clinical Research Center for Cancer Tianjin China
Department of Bioinformatics School of Basic Medical Sciences Tianjin Medical University Tianjin China
Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou China
Scientific Research Center Wenzhou Medical University Wenzhou China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Tianjin Municipality
References (90)
Show source-provided references
1. 10.1038/s41590‐022‐01141‐110.1038/s41590‐022‐01141‐1 ↗
2. 10.1038/s43018‐024‐00794‐110.1038/s43018‐024‐00794‐1 ↗
3. 10.1002/cncr.2862010.1002/cncr.28620 ↗
4. 10.1200/JCO.22.0176310.1200/JCO.22.01763 ↗
5. 10.1200/JCO.23.0113610.1200/JCO.23.01136 ↗
6. 10.1016/j.cell.2015.07.06110.1016/j.cell.2015.07.061 ↗
7. 10.1038/s41591‐023‐02304‐910.1038/s41591‐023‐02304‐9 ↗
8. 10.1038/s41389‐023‐00452‐810.1038/s41389‐023‐00452‐8 ↗
9. 10.1158/2326‐6066.CIR‐17‐032010.1158/2326‐6066.CIR‐17‐0320 ↗
10. 10.1038/ncomms669410.1038/ncomms6694 ↗
11. 10.1080/2162402X.2018.145012710.1080/2162402X.2018.1450127 ↗
12. 10.1158/0008‐5472.CAN‐16‐175510.1158/0008‐5472.CAN‐16‐1755 ↗
13. 10.1038/s43018‐021‐00221‐910.1038/s43018‐021‐00221‐9 ↗
14. 10.1016/j.molmed.2014.06.00510.1016/j.molmed.2014.06.005 ↗
15. 10.1186/s13148‐018‐0587‐810.1186/s13148‐018‐0587‐8 ↗
16. 10.1136/jitc‐2024‐00977410.1136/jitc‐2024‐009774 ↗
17. 10.1261/rna.066282.11810.1261/rna.066282.118 ↗
18. 10.1038/nmeth.304710.1038/nmeth.3047 ↗
19. 10.1038/nsmb.270110.1038/nsmb.2701 ↗
20. 10.1093/nar/gky114110.1093/nar/gky1141 ↗
21. 10.1038/nbt.394710.1038/nbt.3947 ↗
22. 10.1186/s13059‐014‐0554‐410.1186/s13059‐014‐0554‐4 ↗
23. 10.1016/j.rpor.2020.07.00610.1016/j.rpor.2020.07.006 ↗
24. 10.1186/s40169‐019‐0250‐910.1186/s40169‐019‐0250‐9 ↗
25. 10.1172/JCI7895410.1172/JCI78954 ↗
26. 10.1158/1078‐0432.CCR‐13‐312210.1158/1078‐0432.CCR‐13‐3122 ↗
27. 10.1158/2159‐8290.CD‐17‐040110.1158/2159‐8290.CD‐17‐0401 ↗
28. 10.1016/j.cell.2018.04.01210.1016/j.cell.2018.04.012 ↗
29. 10.1016/j.ccell.2019.01.00310.1016/j.ccell.2019.01.003 ↗
30. 10.1016/j.cell.2017.09.02810.1016/j.cell.2017.09.028 ↗
31. 10.15252/embj.20159208110.15252/embj.201592081 ↗
32. 10.1038/ng.321810.1038/ng.3218 ↗
33. 10.1016/j.cub.2010.02.03510.1016/j.cub.2010.02.035 ↗
34. 10.1016/j.cell.2014.05.03510.1016/j.cell.2014.05.035 ↗
35. Verteporfin Inhibits Yap Function Through Up‐Regulating 14‐3‐3sigma Sequestering Yap in the Cytoplasm
36. 10.1038/s41591‐025‐04029‐310.1038/s41591‐025‐04029‐3 ↗
37. 10.3390/ijms26211079910.3390/ijms262110799 ↗
38. 10.1016/j.immuni.2019.03.02410.1016/j.immuni.2019.03.024 ↗
39. 10.1016/j.cell.2015.01.04310.1016/j.cell.2015.01.043 ↗
40. 10.1038/nature2549210.1038/nature25492 ↗
41. 10.1083/jcb.20010909810.1083/jcb.200109098 ↗
42. 10.1038/s41467‐023‐41095‐y10.1038/s41467‐023‐41095‐y ↗
43. 10.1111/jop.1243010.1111/jop.12430 ↗
44. 10.1111/pcmr.1249810.1111/pcmr.12498 ↗
45. 10.1074/jbc.M110.17966310.1074/jbc.M110.179663 ↗
46. 10.1007/978‐1‐4939‐8885‐3_710.1007/978‐1‐4939‐8885‐3_7 ↗
47. 10.1038/s41467‐024‐48653‐y10.1038/s41467‐024‐48653‐y ↗
48. 10.1038/nsmb125010.1038/nsmb1250 ↗
49. 10.1016/j.molcel.2008.10.01310.1016/j.molcel.2008.10.013 ↗
50. 10.1186/s40779‐023‐00468‐610.1186/s40779‐023‐00468‐6 ↗
51. 10.1371/journal.ppat.101197010.1371/journal.ppat.1011970 ↗
52. 10.1016/j.drup.2023.10101510.1016/j.drup.2023.101015 ↗
53. 10.1186/s13073‐024‐01341‐410.1186/s13073‐024‐01341‐4 ↗
54. 10.1038/s42003‐024‐06555‐110.1038/s42003‐024‐06555‐1 ↗
55. 10.1371/journal.pone.015368910.1371/journal.pone.0153689 ↗
56. 10.1126/science.124700510.1126/science.1247005 ↗
57. 10.1038/s41467‐023‐36316‐310.1038/s41467‐023‐36316‐3 ↗
58. 10.1038/s41592‐020‐01011‐410.1038/s41592‐020‐01011‐4 ↗
59. 10.1016/j.cell.2024.10.02110.1016/j.cell.2024.10.021 ↗
60. 10.1186/s13059‐021‐02263‐910.1186/s13059‐021‐02263‐9 ↗
61. 10.1038/s41388‐020‐1362‐910.1038/s41388‐020‐1362‐9 ↗
62. 10.1158/2159‐8290.CD‐17‐112410.1158/2159‐8290.CD‐17‐1124 ↗
63. 10.1016/j.molcel.2016.05.01210.1016/j.molcel.2016.05.012 ↗
64. 10.1200/OP.23.0067510.1200/OP.23.00675 ↗
65. 10.1016/j.ejca.2024.11397610.1016/j.ejca.2024.113976 ↗
66. 10.1016/j.ccell.2025.01.00910.1016/j.ccell.2025.01.009 ↗
67. 10.1186/s12915‐018‐0545‐010.1186/s12915‐018‐0545‐0 ↗
68. 10.31083/JIN3137510.31083/JIN31375 ↗
69. 10.1038/s41467‐023‐36897‐z10.1038/s41467‐023‐36897‐z ↗
70. 10.15252/emmm.20201346610.15252/emmm.202013466 ↗
71. 10.1093/g3journal/jkaa06910.1093/g3journal/jkaa069 ↗
72. 10.1186/s13059‐023‐03087‐510.1186/s13059‐023‐03087‐5 ↗
73. 10.1038/s41467‐022‐29205‐810.1038/s41467‐022‐29205‐8 ↗
74. 10.1038/s41586‐020‐2746‐210.1038/s41586‐020‐2746‐2 ↗
75. 10.1126/science.aao171010.1126/science.aao1710 ↗
76. 10.1038/nature2347710.1038/nature23477 ↗
77. 10.1006/meth.2001.126210.1006/meth.2001.1262 ↗
78. 10.1038/s41586‐021‐03205‐y10.1038/s41586‐021‐03205‐y ↗
79. 10.1093/nar/gkaf01810.1093/nar/gkaf018 ↗
80. 10.7554/eLife.0500510.7554/eLife.05005 ↗
81. 10.1038/s41596‐024‐01020‐z10.1038/s41596‐024‐01020‐z ↗
82. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
83. 10.1038/s41587‐019‐0114‐210.1038/s41587‐019‐0114‐2 ↗
84. 10.1016/j.cels.2019.03.00310.1016/j.cels.2019.03.003 ↗
85. 10.1186/s13059‐020‐1950‐610.1186/s13059‐020‐1950‐6 ↗
86. 10.1021/acs.nanolett.8b0039010.1021/acs.nanolett.8b00390 ↗
87. 10.1186/s13059‐015‐0844‐510.1186/s13059‐015‐0844‐5 ↗
88. G.Korotkevich V.Sukhov N.Budin et al. “Fast Gene Set Enrichment Analysis ” BioRxiv no.2021(2016):060012 https://doi.org/10.1101/060012.10.1101/060012 ↗
89. 10.1038/s41467‐021‐21246‐910.1038/s41467‐021‐21246‐9 ↗
90. 10.1038/s41467‐023‐43980‐y10.1038/s41467‐023‐43980‐y ↗